在Helicobacter pylori感染的根除疗法后,出现地图状红色的风险
Sho Matsumoto1, Mitsushige Sugimoto2, Masakatsu Fukuzawa1
1Department of Gastroenterology and Hepatology, Tokyo Medical University Hospital, Tokyo, Japan.
Helicobacter
|July 10, 2024
概括
在H. pylori根除后,胃癌的风险因素是类似地图的红色,在大约四分之一的患者中发生. 严重的肠道转化和使用酸抑制剂与其发展有关,因此需要密切监测.
科学领域:
- 胃肠病学 胃肠病学
- 在瘤学瘤学.
- 内镜检查是指内镜检查.
背景情况:
- 类似地图的红色是H. pylori根除后胃癌的新发现的内镜风险因素.
- 根除后类似地图的红斑的发病率和风险因素尚未得到充分了解.
研究的目的:
- 为了确定H.pylori根除后一年内类似地图的红色的发生率.
- 评估地图形状红,胃状况和胃癌风险之间的关联.
主要方法:
- 使用"京都胃炎分类"对内镜性胃炎和类似地图的红色的回顾性评估.
- 对328名H. pylori根除疗法前后患者的分析.
主要成果:
- 类似地图的红斑发病率为25.3%,根除后平均1.2年.
- 类似地图的红色与年龄较大,严重缩,肠道代谢,较高的京都分数和胃癌史有关.
- 类似地图的红色的危险因素包括肠道代谢 (OR: 2.794) 和使用酸抑制剂 (OR: 1.948).
- 胃癌的风险在H. pylori阳性患者中增加,这些患者年龄较大,服用酸抑制剂,并且在根除后出现类似地图的红色.
结论:
- 在H. pylori根除一年后,大约四分之一的患者出现地图状的红色.
- 严重的肠道转化和使用酸抑制剂与类似地图的红色发育有关.
- 患有地图状红色的患者需要在监视内镜期间增加注意力,因为可能存在胃癌风险.
关键词:
在Helicobacter Pylori的研究中,缩性缩 (英语:Atrophy atrophy) 是一种损伤.根除疗法是一种根除疗法.胃癌 胃癌 是一种胃癌.肠道代塑性肠道代塑性像地图一样的红色.更多相关视频
相关概念视频
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
348
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
348
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
109
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
109
Peptic Ulcer Disease I: Introduction
162
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
162
Peptic Ulcer Disease IV: Management
85
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
85
Gastritis III: Clinical Manifestations and Management
209
The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
209
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
365
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
365


